他汀联合PPAR-γ激动剂对冠心病患者血浆炎症因子的影响  

A combination of PPAR-γ agonist and statin reduces plasma levels of inflammatory factor in coronary artery disease patients

作　　者：王莹[1] 卢清玉[1] 宋丽萍[1] 张伶[1] 郭云飞[1] 吴昱[1] 

机构地区：[1]北京市海淀医院,北京100080

出　　处：《山东医药》2008年第41期18-20,共3页Shandong Medical Journal

基　　金：北京市海淀区科技项目(K2008063)

摘　　要：目的探讨过氧化物酶体增殖物活化受体-γ激动剂罗格列酮与他汀治疗对冠脉介入的冠心病患者炎症因子水平的影响。方法60例伴2型糖尿病的经冠脉介入治疗的冠心病患者随机分为两组,观察组采用罗格列酮(4 mg/d)联合阿托伐他汀治疗,对照组仅用阿托伐他汀治疗。ELISA方法检测血浆单核细胞趋化蛋白-1(MCP-1)、可溶性细胞间黏附分子-1(sICAM-1)、及可溶性P选择素水平。结果治疗3个月后,观察组血浆MCP-1水平较治疗前明显降低;sICAM-1及C反应蛋白水平较治疗前及对照组治疗后明显降低。结论罗格列酮与他汀联合应用可通过纠正代谢紊乱及抑制慢性炎症反应的途径,为冠心病介入后患者血管并发症的有效防治提供新的手段。Objective To assess the effect of PPAR-γ agonist rosiglitazone on adhesion molecules levels in type 2 diabetes with coronary artery disease （CAD） patients alter percutaneous coronary intervention （PCI）. Methods A total 60 patients with diabetes and CAD who had been undergone PCI were randomized to receive rosiglitazone （4 rag/d） or not for 6 months. Monocyte chemoattractant protein-1 （ MCP-1 ）, soluble intercellular adhesion molecules （ sICAM-1 ）, sP-selectin were measured using ELISA. Results After 3 months rosiglitazone treatment, plasma levels of MCP-1 were reduced from baseline levels. In addition, plasma levels of sICAM-1 and C-reactive protein were reduced from baseline levels and those in the control group. Conclusion PPAR-γagonist may exert potential benefic effect on the vascular endothelium through its anti-inflammatory mechanism and may be useful as a new therapy in patients undergone PCI.

关 键 词：冠状动脉疾病 罗格列酮 趋化因子类 细胞黏附分子 

分 类 号：R541.4[医药卫生—心血管疾病]